Edward Benthall
Angel Investor @ Cambridge Capital Group
Torquay, United Kingdom
Edward Benthall is a funding round investor at Cambridge Capital Group in Torquay focused on 3D Technology and Biotechnology. Edward Benthall is the Chairman at The Eden Trust. Edward Benthall attended University of Cambridge.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Edward Benthall invests in
Stages Edward Benthall invests in
Countries Edward Benthall invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- 3D Technology 1 (50%)
- Biotechnology 1 (50%)
- Health Diagnostics 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| PneumaCare is focused on development of products for diagnosis and monitoring of respiratory disease using novel 3D imaging technology, developed by the University of Cambridge. The Company’s first product is a non–contact respiratory monitoring system for physician assessment, called PneumaScan™, which has clinical applications in a numberof medical environments. Using PneumaScan™, patients can be assessed while breathing naturally or performing spirometric manoeuvres without the need to breathe into, interact with or contact the measuring device.PneumaCare's products, the PneumaScan™ family, enables clinicians to access many different patient-types, many of which are not within the capabilities of current clinical devices. The system is being constantly evaluated in clinical practice, currently at Addenbrooke’s Hospital in Cambridge, Great Ormond Street Children’s Hospital in London and in development laboratories at its design and manufacturing partner, Plextek.PneumaScan™ produces standard medical outputs for a broader portion of the population because it observes patients from a distance and does not impede the respiratory system as with current spirometer technology. Measuring from a distance means lower infection risk, less harm, reduced patient discomfort and minimal instrument running costs from having to replace or sterilise parts which have contacted the patient. | $1.3M / Oct 30, 2013 | ||
| PneumaCare is focused on development of products for diagnosis and monitoring of respiratory disease using novel 3D imaging technology, developed by the University of Cambridge. The Company’s first product is a non–contact respiratory monitoring system for physician assessment, called PneumaScan™, which has clinical applications in a numberof medical environments. Using PneumaScan™, patients can be assessed while breathing naturally or performing spirometric manoeuvres without the need to breathe into, interact with or contact the measuring device.PneumaCare's products, the PneumaScan™ family, enables clinicians to access many different patient-types, many of which are not within the capabilities of current clinical devices. The system is being constantly evaluated in clinical practice, currently at Addenbrooke’s Hospital in Cambridge, Great Ormond Street Children’s Hospital in London and in development laboratories at its design and manufacturing partner, Plextek.PneumaScan™ produces standard medical outputs for a broader portion of the population because it observes patients from a distance and does not impede the respiratory system as with current spirometer technology. Measuring from a distance means lower infection risk, less harm, reduced patient discomfort and minimal instrument running costs from having to replace or sterilise parts which have contacted the patient. | $2.5M / Aug 02, 2011 |
Co-Investors
About Cambridge Capital Group
Cambridge Capital Group (CCG) is a leading business angel group of 70+ investors who have been investing in hi-tech businesses for more than a decade. CCG was formed in the Autumn of 2000 and has been backing tech start-ups in the region ever since. Their members have invested several millions of pounds into more than 30 live portfolio companies inthe Cambridge technology cluster. Membership is an application process, normally following introductions by existing members.Their partner networks are Anglia Capital Group and CCG International, both of which benefit from deal flow developed in Cambridge, Europe's leading hi-tech cluster.
Cambridge Capital Group Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Jayne Parker
Managing Director
|
|||
|
Struan McDougall
Founder & Chairman
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Edward Benthall invest in?
Edward Benthall invests primarily in 3D Technology, Biotechnology and Health Diagnostics startups, most often at Funding Round stage. Most of the 2 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Edward Benthall?
Public channels for Edward Benthall include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Edward Benthall last invest?
The most recent investment recorded for Edward Benthall closed in Oct 2013. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!